2024 has been a pivotal year for biopharma, marked by both challenges and remarkable progress. Milestones like CAR-T therapies gaining approvals for earlier-line cancer treatments and promising antibody-drug conjugate candidates poised for approval in the new year, set the stage for exciting developments in the coming year. As we gear up for 2025, let’s take a moment to reflect on some of Discovery’s highlights from this year.
Discovery Life Sciences
Biotechnology Research
Huntsville, Alabama 23,357 followers
Science at your Service™
About us
Discovery Life Sciences, the Biospecimen and Biomarker Specialists™, is a leading provider of highly characterized human biospecimens and cellular starting materials integrated with expert multi-omic analytical services to advance cell and gene therapy and precision medicine programs for cancer, infectious disease, and other complex conditions. Our robust biospecimen and biomarker platform is optimized for speed and large scale capacity. We routinely manage hundreds of studies and expertly test thousands of biospecimens simultaneously as a single vendor - eliminating time consuming and inefficient transfers of biospecimens or data between different vendors. We offer one of the largest recallable donor pools, Research Use Only (RUO) and clinical-grade (GMP) fresh and cryopreserved human cellular materials to support cell and gene therapy programs at any scale from start to finish. Leading biopharma, diagnostic and academic institutions trust us to quickly deliver high-quality biospecimens and reliable, reproducible biomarker data, so they can outpace their competition and push the leading edge of innovation. Visit www.dls.com to learn more
- Website
-
http://www.dls.com
External link for Discovery Life Sciences
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Huntsville, Alabama
- Type
- Privately Held
- Founded
- 2018
- Specialties
- human clinical samples, cancer tissues, primary cells, peripheral blood mononuclear cells, bone marrow mononuclear cells, whole blood, circulating tumor cells, lab services, blood processing, histology, pathology, protocol development, assay development, clinical targeting, sample pre-screening, data security, analytical services, tissue analysis, molecular testing, flow cytometry analysis, sample validation, quality control, genomic services, and Next-Gen Sequencing
Locations
Employees at Discovery Life Sciences
Updates
-
Read the newest blog about how the quality of donor-derived leukopaks influences the success of gene editing!
High-quality donor-derived leukopaks are essential for progressing ex vivo gene editing applications in HSPC-based gene therapies and CAR-T cell therapies require High-quality donor-derived leukopaks. From mobilization protocols to donor selection, optimization of these factors can improve gene editing efficiency and drive better therapeutic outcomes. Read our new blog post to learn more: https://lnkd.in/eGsv66fi #celltherapy #CART #genetherapy #leukopak
-
Join Discovery at booth #16 during the NextGen Omics & Spatial Biology US. Our team is excited to return to Boston on March 27-28 at the Sheraton Boston Hotel. Stop by to explore how our scalable and comprehensive suite of multi-omics and pathologist-driven services can support your research program and clinical trial needs. Connect with Chris Friedrich and Daphne Georlette, PhD or schedule a private meeting with our team here: https://lnkd.in/dZhA-wra We look forward to seeing you! #NextGenOmics #SpatialBiology
-
-
USCAP is coming soon! Don’t miss the opportunity to schedule a meeting with our expert Biomarker Academy team.
Join us at #USCAP in Boston from March 22-27 and discover how Discovery's Biomarker Academy and Peri-and Post-Approval Services boost lab competency and pathologist proficiency to accelerate the adoption of clinical diagnostic biomarkers through training development, peer-to-peer pathologist training, concordance studies, and more. Reach out to our expert Biomarker Academy team members below to schedule a meeting! - Dr. Gudrun Bänfer, Client Relations and Business Expansion Manager - Riem Adjam, Senior Director Global Peri & Post-Approval Services #USCAP2025
-
-
The on-demand video is now available! In case you missed it, Discovery leaders discussed the cutting-edge 3D tumor models and their potential to accelerate cancer research and development. https://lnkd.in/dMTq9__S Title: Considerations in Tissue Acquisition and Characterization for the Development of Long-Term Tumoroid Models Key Topics include: - Explore how advanced 3D tumor models offer new in vitro capabilities - Understand the importance of a highly annotated biorepository in developing new 3D tumor models - Learn how novel 3D tumor models maintain the heterogeneity of the parent tumor - Discover the applications of 3D tumor models in drug testing and evaluation Speakers: Shawn Fahl, VP Lab Operations, Cell Services & R&D, Biospecimens and Philip McCauley, Product Manager.
-
Join us at #USCAP in Boston from March 22-27 and discover how Discovery's Biomarker Academy and Peri-and Post-Approval Services boost lab competency and pathologist proficiency to accelerate the adoption of clinical diagnostic biomarkers through training development, peer-to-peer pathologist training, concordance studies, and more. Reach out to our expert Biomarker Academy team members below to schedule a meeting! - Dr. Gudrun Bänfer, Client Relations and Business Expansion Manager - Riem Adjam, Senior Director Global Peri & Post-Approval Services #USCAP2025
-
-
Are you attending Precision Med Tri-Con? Stop by Booth 9 to grab a beverage at our hydration station and meet the team. Let’s connect! Shawn Fahl, Meredith Osborn MS, Dan Searson, T. Scott Reid, Andy L. Chiang, Nadia DeStefano #TRICON #TRICON2025
-
-
Colorectal cancer is one of the most common cancers in the US—but it’s also one of the most preventable. When detected early, the five-year relative survival rate is 91.1%.However, this drops significantly as the cancer advances: https://lnkd.in/gEvaJJ8h Early detection saves lives. Routine screening can catch colorectal cancer before it spreads, dramatically improving outcomes. Let’s raise awareness and make regular screening a priority. #ColorectalCancer #Prevention #DressInBlueDay
-
-
Tri-Con 2025 update! Don’t miss Dr. Shawn Fahl at the panel discussions over Tech Trends in Precision Medicine on Wednesday March 12, at 4:05 PM. In this plenary discussion session, Dr. Fahl will join a distinguished panel to share insights on emerging innovations in precision medicine. Attend the poster presentation titled Cell-Free DNA and Beyond: A Comprehensive Evaluation of Liquid Biopsy Workflows Across in a Global Clinical Biorepository See you there! #TRICON #TRICON2025
-
It’s difficult to evaluate the metabolism of large and poorly permeabilized drug compounds in the conventional in vitro liver models due to their size, structure, and limited membrane permeability. Our new blog post explores how these factors impact drug development and how permeabilized hepatocytes offer a novel solution to overcome these challenges. Read the new blog post: https://lnkd.in/edK3NpXP #hepatocytes #ADMET
-